Memorial Sloan Kettering

50288 Newsletter Sum21

Issue link: http://read.uberflip.com/i/1382177

Contents of this Issue

Navigation

Page 1 of 3

my team had for me was inspiring. Even on the most difficult days, they never lost their patience. While those weeks were some of the toughest of my life, my team ensured I never lost faith. My MSK team went above and beyond to support me. When I look up amyloidosis now, I can see that care has improved since my original diagnosis. MSK research over the past decade, including leading-edge clinical trials, is providing exciting new treatment options for people with my disease. That is why I am a member of the Friends of MSK monthly giving program, and why I have included MSK in my estate plans. The gift in my will embodies my goal to leave a positive mark on the world for those who come after me. I was, and continue to be, a lucky recipient of treatments funded by the generosity of past supporters. My greatest wish is that my contributions play a part in saving more lives for generations to come. PAGE 2 Thanks to Dr. Landau and the hematologic oncology team at MSK, Diane has been able to broaden her horizons and enjoy life to the fullest. DIANE'S TALENTED PHYSICIAN Heather Landau, MD, is a hematologist and researcher who cares for patients with blood cancers and plasma cell disorders, including multiple myeloma and amyloidosis. Plasma cell disorders like amyloidosis are characterized by rare mutations in plasma cells, a type of white blood cell, that can undermine a person's immune system. There are currently no cures for plasma cell disorders—but Dr. Landau's work is bringing hope to people affected by them. She is a principal investigator on two MSK clinical trials, one aimed at finding more effective treatments for amyloidosis and another comparing two different regimens for multiple myeloma. "With my MSK colleagues, I am testing a variety of therapies, sometimes in combination with a stem cell transplant, to provide people with more effective and less toxic regimens for plasma cell disorders," says Dr. Landau. Diane's Story Continued from Page 1

Articles in this issue

view archives of Memorial Sloan Kettering - 50288 Newsletter Sum21